Adjunctive Vaginal Progesterone in Management of Preterm Labor

Launched by CHULALONGKORN UNIVERSITY · Aug 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether adding a specific type of vaginal progesterone called micronized progesterone effervescent can help manage preterm labor more effectively when combined with standard treatments. In this trial, half of the women will receive the progesterone along with standard treatment, while the other half will only receive the standard treatment. The goal is to see if the progesterone can help prevent premature delivery, which can be risky for both the mother and the baby.

To participate in this study, women must be pregnant with a single baby between 24 and 33 weeks along and experiencing preterm labor. They should have already received certain medications to help delay labor. However, women who have serious medical issues, certain complications with their pregnancy, or significant cervical changes are not eligible. If you join the trial, you will be closely monitored and receive care throughout the study, helping researchers learn more about how to improve treatments for preterm labor.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • singleton pregnancy with gestational age 24-33 weeks 6 days
• • preterm labor
• • received treatment with tocolysis and corticosteroids
• Exclusion Criteria:
• • conditions that need immediate delivery such as fetal distress, chorioamnionitis
• • have medical complications such as heart disease, seizure
• • fetal anomalies
• • cervical dilatation more than 5 cm
• • allergy to progesterone
• • contraindication to progesterone
• • contraindication to tocolytic use